Posted by Michael Wonder on 09 Feb 2023
Nexus Pharmaceuticals receives FDA approval for tirofiban hydrochloride injection
9 February 2023 - Nexus Pharmaceuticals announced that it has received US FDA approval for tirofiban hydrochloride injection in 5 mg/100 mL single-dose IV bags.
Tentative approval has been granted for concentrations of 12.5 mg/250 mL single-dose IV bags. It is an AP rated generic to Aggrastat.
